Kahalalide F vs Plitidepsin
Head-to-head comparison of Kahalalide F (Kahalalide F) and Plitidepsin (Dehydrodidemnin B (Plitidepsin)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Kahalalide F | Plitidepsin |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Kahalalide F | Dehydrodidemnin B (Plitidepsin) |
| Molecular Weight | 1111.3 Da | 1110.3 Da |
| Half-Life | N/A | Approximately 44 hours |
| Amino Acids | N/A | N/A |
| Typical Dose | 0.1-3 mg/m2 IV in early trials | 1.5 mg/m2 IV |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 240 |
| Research Status | Pre-clinical | Clinical |
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
Plitidepsin Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓anti-inflammatory
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
Plitidepsin Dosing
1.5 mg/m2 IV infusion in oncology trials|q21d or similar intermittent schedules|dose escalation and combination protocols in studies
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
Plitidepsin Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠transaminase elevation
Research Overview
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
Plitidepsin
Plitidepsin has been studied for its ability to disrupt eEF1A-dependent pathways, induce oxidative stress, and suppress tumor cell growth. It has reached clinical oncology development and was also evaluated as a candidate against SARS-CoV-2 in the literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.